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Methotrexate is a disease-modifying antirheumatic drug commonly used to treat inﬂammatory conditions such as rheumatoid
arthritis which itself is linked to increased cardiovascular risk. Treatments that target inﬂammation may also impact the
cardiovascular system. While methotrexate improves cardiovascular risk, inhibition of the cyclooxygenase (COX)-2 enzyme
promotes atherosclerosis. These opposing cardiovascular inﬂuences may arise from diﬀering eﬀects on the expression of proteins
involved in cholesterol homeostasis. These proteins, ATP-binding cassette transporter (ABC) A1 and cholesterol 27-hydroxylase,
facilitate cellular cholesterol eﬄux anddefend againstcholesterol overload. Methotrexate upregulates expression ofcholesterol 27-
hydroxylase and ABCA1 via adenosine release, while COX-2 inhibition downregulates these proteins. Adenosine, acting through
the A2A and A3 receptors, may upregulate proteins involved in reverse cholesterol transport by cAMP-PKA-CREB activation
and STAT inhibition, respectively. Elucidating underlying cardiovascular mechanisms of these drugs provides a framework for
developing novel cardioprotective anti-inﬂammatory medications, such as selective A2A receptor agonists.
1.Introduction
Rheumatoid arthritis is a multisystem autoimmune disorder
[1]. Inﬂammatory processes in rheumatoid arthritis lead
to accelerated atherosclerosis and aﬄicted patients have an
elevated risk for cardiovascular events leading to a higher
mortality [1]. In particular, elevated levels of immune com-
plexes and cytokines (tumor necrosis factors, interleukins,
and interferons (IFN)) contribute to the pathogenesis of
both the articular [2] and cardiovascular manifestations of
rheumatoid arthritis [3]. As such, the cardiovascular actions
of antiarthritic medications are an important determinant
for multiple aspects of patient care [3].
Although traditional nonsteroidal anti-inﬂammatory
drugs (NSAIDs)[4], cyclooxygenase (COX)-2 inhibitors [5],
methotrexate [6], and otherdisease-modifying antirheumat-
ic drugs (DMARDs) are eﬀective treatments for pain and
inﬂammation, each of these drugs is linked with particu-
lar adverse eﬀects which necessitate consideration. While
NSAIDs are associated with gastrointestinal complications
[7], some COX-2 inhibitors are associated with an elevated
risk of cardiovascular events [5]. The COX-2 inhibitor
cardiovascular risk has resulted in a market recall of several
of these medications [8]. Although still associated with some
adverse eﬀects, methotrexate has proven to be one of the
safest antirheumatic drugs [9].
In contrast to COX-2 inhibitors, methotrexate has
demonstrated atheroprotective properties [10]. Recent stud-
ies have begun unravelling the molecularinteractions under-
pinning the cardiovascular inﬂuence of COX-2 inhibition
[11, 12]a n dm e t h o t r e x a t e[ 13]. While these drugs have mul-
tiple cellular eﬀects, cardiovascular modulation in part relies
upon the regulation of reverse cholesterol transport [13, 14].
This review aims to provide an overview of the mechanisms
by which methotrexate interacts with cholesterol homeosta-
sis to modulate atherogenesis in inﬂammatory disease.
2.Mechanism ofActionofMethotrexate
Methotrexate is an anti-inﬂammatory medication com-
monly used in the treatment of rheumatoid arthritis and2 Cholesterol
other inﬂammatory diseases such as psoriasis and inﬂam-
matory bowel disease [9]. The primary anti-inﬂammatory
actions of methotrexate are attributable to adenosine release,
triggered by methotrexate’s polyglutamate metabolites [6].
Adenosine, a nucleoside produced by many cells and
tissues in response to physical or metabolic stresses, is an
endogenous anti-inﬂammatory mediator [15]. The phys-
iological eﬀects of adenosine are mediated by G-protein
coupled 7-transmembrane receptors [16]t h a te x i s to n
almost all human cell types [15]. Adenosine receptors are
divided into four classes, A1,A 2A,A 2B,a n dA 3,b a s e do nt h e
diﬀerential selectivity of adenosine analogues and molecular
structure [15].
It has been noted that some of the anti-inﬂammatory
eﬀects of methotrexate may be reversed by inhibition
of the A2A receptor [17]. Further research suggests that
stimulation of the A2A receptor interferes with inﬂammatory
processes such as the biosynthesis and release of proinﬂam-
matorycytokines,inhibitsoxidativeactivity,preventsplatelet
aggregation, and reduces adhesion and degranulation of
neutrophils [18]. Together these results demonstrate that the
A2A receptor plays a signiﬁcant role in the mediation of
inﬂammation [17, 18].
Although adenosine has anti-inﬂammatory properties
principally through its A2A[17]a n dA 3 [19] receptors, it
can also act in contradictory fashions via alternate receptors
[20]. Ligation of adenosine to the A1 receptor initiates
inﬂammatory processes [20]. The adenosine receptors inﬂu-
enceinﬂammatory processesbymodulatingcAMPsignalling
cascades [20]. In particular, the opposing eﬀects of A2A and
A1activation are accounted for, respectively, by an elevation
or reduction in intracellular cAMP [20]. Consequently,
the overall eﬀect of adenosine on inﬂammatory processes
depends upon the relative temporal and spatial distribution
of the various adenosine receptors, as well as the inﬂuence of
other eﬀectors in the inﬂammatory milieu [20].
3. Atherosclerosisand Reverse
CholesterolTransport
3.1. Atherosclerotic Development. Atherosclerosis, an under-
lyingcauseofmyocardialinfarction andstroke,isanintricate
process that comprises elements of both inﬂammation
and lipid accumulation, characterized by the thickening of
arterialwallsduetothedevelopmentofaﬁbrousplaque[21].
When lipid load processing is inadequate in the monocyte
inﬁltrated subendothelial intimia [22], unregulated choles-
terol depositions in macrophages transform them into foam
cells,marking theformationoffatty streaks[21].Subsequent
development forms a ﬁbrous plaque narrowing the arterial
lumen [21].
3.2. Reverse Cholesterol Transport. One of the initiating fac-
torsinthedevelopmentofatherosclerosisisa deregulationof
cholesterol homeostatic mechanisms [23]. The metabolism
and removal of excess cholesterol is required to prevent
foam cell accumulation [24]. Reverse cholesterol transport
(RCT) is the process that transports such cholesterol from
extrahepatic cells to the liver and intestine for excretion
[25]. By preventing lipid accumulation via the control
of cholesterol eﬄux, RCT pathways provide a defensive
mechanism againstproatherogeniccholesteroloverload[25].
Extrahepatic cells eliminate intracellular cholesterol via
multiple mechanisms of RCT, including adenosine triphos-
phate binding cassette transporter (ABC) A1 [26], ABCG1
[27], and cholesterol 27-hydroxylase (27-hydroxylase) [28]
pathways.CholesterolmayberemovedtoHDLusingABCA1
[26]a n dA B C G 1[ 27] or processed within the cell by 27-
hydroxylase prior to passive diﬀusion [28].
3.3. ABCA1: Adenosine Triphosphate-Binding Cassette Trans-
porter A1. Excess cholesterol within the cell may be actively
transported outward to maintain cholesterol balance [25].
In particular, ABCA1 acts as a rate-controlling transporter
in this cholesterol eﬄux process [26]. Interactions of
apolipoproteins with cholesterol-loaded cells stimulate the
ABCA1mediated transport ofcholesterol and phospholipids
toextracellularapoA-I[26].Aseriesofsubsequentmodiﬁca-
tions ultimately lead to hepatic uptake and biliary excretion
of cholesterol [29].
Mutations in ABCA1 cause a severe HDL deﬁciency
syndrome known as Tangier disease [30]. The reduction
in apoA-I initiated eﬄux of cholesterol leads to the accu-
mulation of lipid deposits in tissues throughout the body
[30]. Consequently, patients with this disease have a marked
increase in the risk of coronary artery disease [31].
Although ABCA1 is normally constitutively expressed,
in grossly atherosclerotic tissue, ABCA1 protein is reduced
despite upregulation in ABCA1 mRNA [32]. This suggests
that in the progression of atherosclerosis, posttranscrip-
tional processes prevent the formation of ABCA1 [32].
Lee-Rueckert et al. [33]h a v ed e m o n s t r a t e dt h a tA B C A 1
expression is signiﬁcantly attenuated by acidiﬁcation. Since
atherosclerotic tissue is gradually acidiﬁed as the lesion
advances, this acid-dependent downregulation may partially
account for the observed decrease in ABCA1 [34]. Given the
association between ABCA1 mutation and atherosclerosis
[31]a sw e l la st h eo b s e r v a n c eo fA B C A 1d o w n r e g u l a t i o n
in atherogenesis [32], support is given to the notion that
the dysregulation of ABCA1 facilitates the development of
atherosclerosis.
3.4. Cholesterol 27-Hydroxylase. Although ABC-dependent
RCT is the primary mechanism of cholesterol removal
[26], the 27-hydroxylase pathway provides an alternative
to the apoA-I-dependent process [28]. The mitochondrial
cytochrome P450 27-hydroxylase enzyme is involved in the
ﬁrst oxidation step of cholesterol in the “acidic” pathway for
biosynthesis of bile acids [35]. 27-hydroxylase is expressed
at high levels in the THP-1 human monocytoid cell line,
macrophages, and principal cell types in the atherogenic
process such as human arterial endothelium and monocytes
[35].
27-hydroxylase catalyzes the conversion of cholesterol
to 27-hydroxycholesterol and subsequently 3-β-hydroxy-5-
cholestenoic acid [36]. Eﬀectively, this enzyme convertsCholesterol 3
cholesterol into an oxygenated derivative or oxysterol. Such
oxysterols are generally present in trace quantities, but their
levels rise within atheromas [37]. The rapid excretion and
degradation of these oxysterols is facilitated by their ability
to pass lipophilic membranes [12, 38].
In atheroma, the dominant oxysterol is 27-hydroxycho-
lesterol, at levels up to one-hundred times greater than in
circulation [37, 39]. Given the faltering ability of ABCA1 to
initiate RCT in advanced atheromas [32], the 27-hydroxylase
mediated eﬄux pathway represents a major remaining
defensive mechanism against excess cholesterol loading [38].
3.5. ABCA1 and 27-Hydroxylase Expression. At the level of
gene expression, an interconnecting factor exists between
ABCA1 and 27-hydroxylase [40, 41]. Oxysterols, includ-
ing 27-hydroxycholesterol, bind and activate the liver X
receptors (LXR) [40]. This interaction induces the nuclear
translocation of an LXR-retinoid X receptor heterodimer, a
transcription factor, which promotes the expression [42]o f
cholesterol metabolism genes, particularly ABCA1 [41].
4.Immunological and Inﬂammatory
ProcessesinAtherogenesis
Accumulating evidence indicates that the systemic inﬂam-
matory load in lupus disrupts cholesterol dynamics, increas-
ing vulnerability to cholesterol accumulation in cells of
the artery wall, including macrophages and endothelium
[43]. Patients with lupus [44] and rheumatoid arthritis
[1] are known to have an increased risk for atheromatous
cardiovascular disease. The immune-complex dysregulation
seen in these conditions may play a role in the atherogenic
process, a notion supported by evidence from cholesterol
loading and eﬄux [44, 45].
In some inﬂammatory disease, antibodies to oxidized
LDL are generated [45]. The resulting formation of
oxLDL-antibody complexes enhances uptake of oxLDL into
macrophages and promotes foam cell formation [44, 45].
Furthermore, stimulation of cultured human monocytes
and THP-1 human monocytoid cells with the immune
reactants IFN-γ or immune complexes impede cellular
cholesteroleﬄuxbymarkedlydecreasing27-hydroxylaseand
ABCA1 [46]. Collectively, these immune and inﬂammatory
mediators promote atherosclerosis by disabling mechanisms
thatpreventthecellsoftheartery wallfrombeingoverloaded
with cholesterol,leading totheformation oflipidladenfoam
cells [46, 47].
Research suggests that IFN-γ inhibits RCT by modifying
signal transducer and activator of transcription (STAT)
protein activity via two alternate mechanisms [48, 49]. In
the ﬁrst process, IFN-γ binds to the IFN receptor, initiating
the dimerization of the two IFN-γ receptor sub-units
which phosphorylates the bound janus kinases [48, 50].
The activated kinase phosphorylates the IFN-γ receptor,
recruiting STAT proteins [50]. These STAT proteins are
tyrosine phosphorylated, dimerize and translocate to the
nucleus, where they downregulate LXRα,w h i c hi nt u r n
decreases ABCA1 expression [48].
In the second process, IFN-γ induces a calcium ﬂux
which activates the calcium/calmodulin-dependent protein
kinase II (CaMKII) [49]. CaMKII directs the phosphoryla-
tionoftheSTATresidue,Ser727 which maximizes STATactiv-
ity [51]. The ability of both immune complexes and IFN-γ
to inﬂuence RCT and macrophage to foam cell conversion
emphasizes the importance of cardiovascular considerations
in the treatment of inﬂammatory autoimmune disorders
[47].
5.Mechanisms forMethotrexate
Inﬂuence onReverseCholesterol
Transportand Atherosclerosis
Across a multiplicity of reviewed studies, COX-2 inhibition
elevated cardiovascular risk [5] while methotrexate signif-
icantly reduces cardiovascular disease mortality amongst
rheumatoid arthritis patients [10], despite some disagree-
ment for patients with prior atherosclerotic development
[52]. Given the fundamental role of ABCA1 and 27-
hydroxylase in regulating foam cell formation, we postulated
a potential role for RCT in the atherosclerotic eﬀects fol-
lowing treatment with COX-2 inhibitors and methotrexate
[13]. The application of COX-2 inhibitors to THP-1 mono-
cytes cultures resulted in signiﬁcant decreases in the gene
expression of 27-hydroxylase and ABCA1[14]. The resultant
reduction in ABCA1 and 27-hydroxylase protein creates
an environment where cholesterol eﬄux is compromised,
promoting foam cell formation [14].
Signiﬁcantly, the eﬀects of COX-2 inhibition on choles-
terol metabolism and eﬄux may be reversed by the addition
ofadenosineA2A receptoragonists[11].Giventhepreviously
described ability ofmethotrexate to induceadenosine release
[6], it is plausible that methotrexate is capable of upregulat-
ing RCT as its mechanism for atheroprotection.
UsingRT-PCR andimmunoblotting,the levelsof expres-
sion of ABCA1 and 27-hydroxylase were evaluated in cells
in the presence of COX-2 inhibitors or IFN-γ with or
without methotrexate [13]. Methotrexate reversed foam
c e l lf o r m a t i o na n dt h ed o w nr e g u l a t i o no fA B C A 1a n d
27-hydroxylase induced by COX-2 inhibition or IFN-γ
[13]. However, this methotrexate-induced upregulation was
prevented by an inhibition of adenosine A2A receptors [13].
Thus, the capacity of methotrexate to reduce the onset of
atherosclerosis may be partially attributed to the adenosine-
driven upregulation of ABCA1 and 27-hydroxylase which
expedites cholesterol eﬄux [13].
Thespeciﬁc mechanism bywhichadenosineA2A receptor
ligation modiﬁes 27-hydroxylase and ABCA1 expression has
not yet been elucidated [12]. However, the inhibition of
PKA prevents adenosine A2A stimulation of RCT proteins,
demonstrating a dependency upon a cAMP-PKA-mediated
process [46]. Generally, A2A receptor ligation activates
adenylate cyclase, leading to the accumulation of cAMP
[53]. cAMP activates PKA which subsequently activates
CREB proteins [46] .T h e s ep r o t e i n st h e nt r a n s l o c a t ei n t o
the nucleus, where it interacts with a consensus element in4 Cholesterol
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Figure 1: Regulation of adenosine triphosphate binding cassette transporter A1 (ABCA1) expression by adenosine. Methotrexate via
numerous steps (jagged arrow) results in increased levels of adenosine. Adenosine activates the G-protein coupled receptor, A2A,i n d u c i n g
an increase in adenylyl cyclase activity. The subsequent rise in cyclic adenosine monophosphate (cAMP) activates protein kinase A (PKA)
which phosphorylates the cAMP response element-binding protein (CREB). CREB then translocates into the nucleus where it upregulates
ABCA1 gene expression.
the gene promoter, modulating the expression of the target
gene [46]( Figure 1).
As previously discussed, 27-hydroxycholesterol upregu-
lates ABCA1 expression [40, 41]. A reasonable hypothesis is
that ABCA1 upregulation is dependent upon the increased
expression of 27-hydoxylase. However, inhibition of the 27-
hydroxylase enzyme does not hinder the ability of adenosine
A2A ligation to upregulate ABCA1, suggesting that the
methotrexate-induced increase in ABCA1 expression is not
contingent on this feedback loop [46].
In addition to stimulating increased ABCA1 expression,
A2A ligation augments ABCA1 activity [54]. The generation
of cAMP by A2A stimulation activates protein kinases and
Epac[54],aguanine nucleotideexchange factor[55].Protein
kinasegeneratesphospho-ABCA1andEpacactivates ABCA1
function [54]. Thus, methotrexate promotes cholesterol
eﬄux and hinders atherogenesis by both upregulating and
activating RCT proteins.
Beyond the A2A receptor, adenosine may counteract the
eﬀects of IFN-γ via the A3 receptor [49]. The addition
of adenosine to IFN-γ stimulated cells decreases ser727
phosphorylation, thereby reducing STAT activity [49]. This
decrease in STAT activity decreases the expression of genes
involvedininﬂammation andlipiduptake[48].Inhibitionof
the A3 receptor reverses the suppressive eﬀects of adenosine
on STAT ser727 phosphorylation [49]. Given the role of
STAT in suppressing RCT [48], this activity may additionally
contribute to the antiatherosclerotic actions of methotrexate
[49]. Although the A3-mediated pathway has yet to be
uncovered, it has been demonstrated that A3 receptor
activation preventsthe accumulationofCa2+ [56]. Thus, it is
possible that A3 activity prevents the activation of CaMKII,
which subsequently reduces the phosphorylation of ser727
[49]( Figure 2).
6.Conclusion
While methotrexate improves cardiovascular risk in a
number of inﬂammatory diseases [10], COX-2 inhibitionCholesterol 5
ABCA1 expression
+
Adenosine
+
IFN receptor
JAK JAK G-protein
+
CaMKII
P
P
STAT STAT
P
P Y
Y
S
S
Nucleus
+
+
+
+
HO
OH
OH
N
N
N
N
NH2
O
IFN-γ
LXRα expression
−
−
−
−
−
A3 receptor
Ca2+
Figure2:Abrogationofinterferon(IFN)-γ mediateddownregulationofadenosinetriphosphatebindingcassettetransporterA1(ABCA1)by
adenosine A3 receptor ligation. IFN-γ binds the IFN receptor and subsequently decreases ABCA1 expression by increasing signaltransducer
and activator of transcription (STAT) protein activity via tyrosine (Y) and serine (S) phosphorylation. The IFN receptor induces a janus-
kinase mediated process which tyrosine phosphorylates STAT. The serine is phosphorylated by a calcium/calmodulin-dependent protein
kinase II (CaMKII) activated by a calcium ﬂux initiated by the IFN receptor. These activated STAT proteins dimerize and translocate to the
nucleus, where they downregulate liver X receptor (LXR)α. While LXR normally upregulates ABCA1 expression, a decrease in LXR results
in a consequent decrease in ABCA1 expression. Signiﬁcantly, adenosine may counteract the eﬀects of IFN-γ on ABCA1 via the A3 receptor.
A3 activation prevents the accumulation of Ca2+ and may thus prevent the activation of CaMKII. This reduced activity will decrease the
phosphorylation of S727 on STAT, decreasing STAT activity and thus preventing the downregulation of ABCA1.
promotes atherosclerosis [5]. These opposing cardiovascular
inﬂuences of methotrexate and COX-2 inhibitors may arise
from diﬀering eﬀects on the expression of ABCA1 and 27-
hydroxylase, key proteins in RCT [25]. While methotrexate
upregulates their expression [13], COX-2 inhibition causes a
downregulation [14]. Methotrexate increases the expression
of these proteins via adenosine acting upon the A2A [13]a n d
A3 receptors [49]. Activation of A2A increases expression of
the proteins and activity of ABCA1 by a cAMP-mediated
process [46]w h i l et h eA 3 receptor counteracts the IFN-
γ induced downregulation by inhibiting STAT [49]. Fur-
thermore, as proposed in the Cardiovascular Inﬂammation
Reduction Trial, methotrexate administration may provide
additional antiatherosclerotic beneﬁts in patients already
receiving traditional cholesterol-lowering therapy, regardless
ofinﬂammatory disease status[57].Thus, theunderstanding
of the mechanisms by which these medications act to induce
cardiovascular eﬀects provides a platform for the design of
novel and safer anti-inﬂammatory and antiatherosclerotic
drugs in the future, such as selective adenosine A2A receptor
agonists.
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